The Oxford Optimisation of PCI Study (OXOPT-PCI Study) (OXOPT-PCI)
Primary Purpose
Coronary Artery Disease
Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Optimisation of the result of intracoronary stenting according to specific algorithm
Sponsored by

About this trial
This is an interventional treatment trial for Coronary Artery Disease
Eligibility Criteria
Inclusion Criteria:
- participant is willing and able to give informed consent for participation in the study
- angiogram shows haemodynamically relevant lesion suitable for PCI and suitable for the use of intravascular imaging (OCT)
Exclusion Criteria:
- patients in whom safety or clinical concerns preclude participation
- ST-segment elevation myocardial infarction
- presentation with cardiogenic shock
- revascularization by mean of balloon angioplasty without stenting
- contraindications to adenosine
Sites / Locations
- Oxford University Hospital - NHS Trust
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
PCI optimisation
No PCI optimisation
Arm Description
Post PCI FFR below 0.9
Post PCI FFR 0.9 or higher
Outcomes
Primary Outcome Measures
Final Fractional Flow Reserve (FFR) After Intracoronary Stenting
After administration of intracoronary nitrates, FFR was measured under maximal hyperaemia, using intravenous adenosine (140 mg kg-1 min-1) as the ratio between distal coronary pressure (Pd) and aortic pressure (Pa)
Secondary Outcome Measures
Number of Participants With Stent-edge Dissection Assessed by OCT
Defined as presence of a linear rim of tissue ≥200 μm in width and with clear separation from the vessel wall, or underlying plaque <5 mm from stent edges
Number of Participants With Reference Lumen Narrowing (Geographical Miss) Assessed by OCT
Defined as reference lumen area <4.5 mm2, with significant residual plaque within 10 mm of stent edges
Number of Participants With Stent Malapposition Assessed by OCT
Defined as stent-adjacent vessel lumen distance > 200 μm
Number of Participants With Plaque/Thrombus Protrusion Assessed by OCT
Defined as tissue prolapsing between stent struts extending inside a circular arc connecting adjacent struts or intraluminal mass ≥500 μm thick with no direct connection to the vessel wall, or highly backscattered luminal protrusion in continuity with the vessel wall, resulting in signal-free shadowing
Number of Participants With Stent Under-expansion Assessed by OCT
Defined as minimal stent area (MSA) < 70% of average reference lumen area and/or MSA < 4.5 mm2
Full Information
NCT ID
NCT03111940
First Posted
June 12, 2016
Last Updated
March 12, 2021
Sponsor
Oxford University Hospitals NHS Trust
1. Study Identification
Unique Protocol Identification Number
NCT03111940
Brief Title
The Oxford Optimisation of PCI Study (OXOPT-PCI Study)
Acronym
OXOPT-PCI
Official Title
The Oxford Optimisation of PCI Study (OXOPT-PCI Study)
Study Type
Interventional
2. Study Status
Record Verification Date
March 2021
Overall Recruitment Status
Completed
Study Start Date
August 2016 (Actual)
Primary Completion Date
July 2017 (Actual)
Study Completion Date
July 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Oxford University Hospitals NHS Trust
4. Oversight
5. Study Description
Brief Summary
The OxOPT-PCI study addresses patients with coronary artery disease who are referred to the John Radcliffe Hospital because of the need for treatment with an intra-coronary stent (metal scaffold) for clinical reasons. Although, this has become a highly standardised procedure it is still challenging for the clinician to assess the final success of this procedure at the end of intervention with conventional methods. This shortcoming can potentially translate into a worse clinical outcome for approximately 10 percent of all patients treated with an intra-coronary stent for this type of disease.
This study (OxOPT-PCI) investigates if the use of blood flow measurements (namely measurement of fractional flow reserve (FFR)) and intravascular imaging (namely optical coherence tomography (OCT)) after the implantation of a stent can improve the treatment result for these patients. Both, FFR and OCT are being used already in daily clinical routing but their usefulness especially in combination is not clear. In order to standardise the optimisation procedure we developed a specific algorithm to make sure that all patients receive the same optimisation measures based on the assessment of FFR and OCT.
The benefit of this specific optimisation algorithm will be assessed by measuring 1) indices of coronary blood flow, 2) intravascular imaging at the end of the procedure, and 3) by contacting the patients 12 months after stenting to verify the clinical mid-term success.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
35 (Actual)
8. Arms, Groups, and Interventions
Arm Title
PCI optimisation
Arm Type
Experimental
Arm Description
Post PCI FFR below 0.9
Arm Title
No PCI optimisation
Arm Type
No Intervention
Arm Description
Post PCI FFR 0.9 or higher
Intervention Type
Procedure
Intervention Name(s)
Optimisation of the result of intracoronary stenting according to specific algorithm
Primary Outcome Measure Information:
Title
Final Fractional Flow Reserve (FFR) After Intracoronary Stenting
Description
After administration of intracoronary nitrates, FFR was measured under maximal hyperaemia, using intravenous adenosine (140 mg kg-1 min-1) as the ratio between distal coronary pressure (Pd) and aortic pressure (Pa)
Time Frame
Immediately post-stenting for Group 1A and 1B, and post FFR/OCT-guided optimisation for Group 1A
Secondary Outcome Measure Information:
Title
Number of Participants With Stent-edge Dissection Assessed by OCT
Description
Defined as presence of a linear rim of tissue ≥200 μm in width and with clear separation from the vessel wall, or underlying plaque <5 mm from stent edges
Time Frame
During PCI procedure, OCT typically adds 5 minutes to the procedure
Title
Number of Participants With Reference Lumen Narrowing (Geographical Miss) Assessed by OCT
Description
Defined as reference lumen area <4.5 mm2, with significant residual plaque within 10 mm of stent edges
Time Frame
During PCI procedure, OCT typically adds 5 minutes to the procedure
Title
Number of Participants With Stent Malapposition Assessed by OCT
Description
Defined as stent-adjacent vessel lumen distance > 200 μm
Time Frame
During PCI procedure, OCT typically adds 5 minutes to the procedure
Title
Number of Participants With Plaque/Thrombus Protrusion Assessed by OCT
Description
Defined as tissue prolapsing between stent struts extending inside a circular arc connecting adjacent struts or intraluminal mass ≥500 μm thick with no direct connection to the vessel wall, or highly backscattered luminal protrusion in continuity with the vessel wall, resulting in signal-free shadowing
Time Frame
During PCI procedure, OCT typically adds 5 minutes to the procedure
Title
Number of Participants With Stent Under-expansion Assessed by OCT
Description
Defined as minimal stent area (MSA) < 70% of average reference lumen area and/or MSA < 4.5 mm2
Time Frame
During PCI procedure, OCT typically adds 5 minutes to the procedure
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
participant is willing and able to give informed consent for participation in the study
angiogram shows haemodynamically relevant lesion suitable for PCI and suitable for the use of intravascular imaging (OCT)
Exclusion Criteria:
patients in whom safety or clinical concerns preclude participation
ST-segment elevation myocardial infarction
presentation with cardiogenic shock
revascularization by mean of balloon angioplasty without stenting
contraindications to adenosine
Facility Information:
Facility Name
Oxford University Hospital - NHS Trust
City
Oxford
ZIP/Postal Code
OX3 9DU
Country
United Kingdom
12. IPD Sharing Statement
Learn more about this trial
The Oxford Optimisation of PCI Study (OXOPT-PCI Study)
We'll reach out to this number within 24 hrs